Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EEG-guided Duloxetine vs Bupropion in MDD
NCT04388189Phase 4Withdrawn
- Sponsor
- Alto Neuroscience
- Start
- Oct 2020
- Primary completion
- May 2023
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of duloxetine, bupropion in major depressive disorder (MDD), sponsored by Alto Neuroscience. Planned start Oct 2020; status: withdrawn.
02
Drugs
duloxetinebupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04388189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04388189.